How many stocks are there of Biotron?
The current number of stocks of Biotron is 902.17 M undefined.
Biotron Stocks 2025
Biotron Stocks
902.17 M
Ticker
BIT.AX
ISIN
AU000000BIT4
WKN
602346
In 2025, Biotron had 902.17 M outstanding stocks, a 9.91% change from the 820.84 M stocks in the previous year.
The Biotron Stocks history
| YEAR | NUMBER OF STOCKS (undefined AUD) |
|---|---|
| 2024 | 902.17 |
| 2023 | 820.84 |
| 2022 | 724.76 |
| 2021 | 724.76 |
| 2020 | 675.44 |
| 2019 | 577.48 |
| 2018 | 452.06 |
| 2017 | 395.9 |
| 2016 | 361.88 |
| 2015 | 301.53 |
| 2014 | 280.89 |
| 2013 | 280.89 |
| 2012 | 231.5 |
| 2011 | 157.3 |
| 2010 | 142.83 |
| 2009 | 131.16 |
| 2008 | 115.74 |
| 2007 | 110.42 |
| 2006 | 90.12 |
| 2005 | 85.88 |
Biotron shares outstanding AU000000BIT4 · 602346
The number of shares was Biotron in 2024 — This indicates how many shares 902.17 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Biotron earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Biotron's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Biotron’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biotron's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 85.88 M Aktien |
| 2006 | 90.12 M Aktien |
| 2007 | 110.42 M Aktien |
| 2008 | 115.74 M Aktien |
| 2009 | 131.16 M Aktien |
| 2010 | 142.83 M Aktien |
| 2011 | 157.3 M Aktien |
| 2012 | 231.5 M Aktien |
| 2013 | 280.89 M Aktien |
| 2014 | 280.89 M Aktien |
| 2015 | 301.53 M Aktien |
| 2016 | 361.88 M Aktien |
| 2017 | 395.9 M Aktien |
| 2018 | 452.06 M Aktien |
| 2019 | 577.48 M Aktien |
| 2020 | 675.44 M Aktien |
| 2021 | 724.76 M Aktien |
| 2022 | 724.76 M Aktien |
| 2023 | 820.84 M Aktien |
| 2024 | 902.17 M Aktien |
Biotron Aktienanalyse
What does Biotron do?
Biotron Ltd is a company that focuses on the research and development of antiviral drugs. The company was founded in 2000 by Dr. Michelle Miller, who previously worked as a senior researcher in the field of antiviral drug development at a leading pharmaceutical company. Biotron's main business is the development of drugs used to treat viral diseases such as HIV/AIDS, hepatitis B and C, influenza, and Ebola. The company focuses on the development of so-called direct-acting antiviral drugs, which target the virus itself and inhibit its replication. Biotron has made significant progress in the development of such drugs in recent years and currently has several drugs in clinical development. The company works closely with universities, research institutions, and other companies to advance its research and development program. Biotron's business model is based on collaboration with other companies in the field of antiviral drug development. The company works closely with other pharmaceutical companies, hospitals, and government agencies to share its research findings and technologies and bring its drugs to market. The company has two main divisions: research and development, and production and distribution. In the research and development division, Biotron focuses on the development of new drugs that target viruses. The production and distribution division encompasses the production and marketing of these drugs once they are approved for use. As part of its research and development work, Biotron has developed several promising products. One of them is BIT225, a drug used to treat hepatitis C. BIT225 is a direct-acting antiviral drug that targets a specific protein in the virus membrane and inhibits its replication. Another promising product from Biotron is BIT571, a drug used to treat influenza. BIT571 targets a specific type of virus known as Liana or influenza hemagglutinin virus. It has been shown that BIT571 has potent antiviral activity against this type of virus. In addition to BIT225 and BIT571, there are other drugs in clinical development at Biotron. Overall, Biotron has an extensive portfolio of antiviral drugs in various stages of clinical development. In recent years, Biotron has also made significant progress in the production and marketing of its drugs. The company has formed partnerships with other companies in the pharmaceutical manufacturing industry to ensure that its drugs can be produced and brought to market on a large scale. In summary, Biotron Ltd is an emerging company in the field of antiviral drug development. The company has made significant progress in the development of new drugs in recent years and works closely with other companies and research institutions to expand its portfolio. With its promising pipeline of antiviral drugs and strong partnerships with other companies, Biotron has the potential to become a major player in the pharmaceutical industry in the coming years. Biotron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Biotron's Shares Outstanding
Biotron's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Biotron’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Biotron’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Biotron’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Biotron stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Biotron are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Biotron evolved in recent years?
The number of shares of Biotron has increased by 9.91% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Biotron as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Biotron?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Biotron pay?
Over the past 12 months, Biotron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biotron is expected to pay a dividend of 0 AUD.
What is the dividend yield of Biotron?
The current dividend yield of Biotron is .
When does Biotron pay dividends?
Biotron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biotron?
Biotron paid dividends every year for the past 0 years.
What is the dividend of Biotron?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biotron located?
Biotron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biotron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biotron from 2/19/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 2/19/2025.
When did Biotron pay the last dividend?
The last dividend was paid out on 2/19/2025.
What was the dividend of Biotron in the year 2024?
In the year 2024, Biotron distributed 0 AUD as dividends.
In which currency does Biotron pay out the dividend?
The dividends of Biotron are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biotron
Our stock analysis for Biotron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
